Recent clinical trials of mTOR-targeted cancer therapies

Aruni S.Arachchige Don, X. F.Steven Zheng

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


The mammalian target of rapamycin (mTOR) is a central component within a complex intracellular signaling network that regulates various processes including cell growth, proliferation, metabolism, and angiogenesis. A hyperactive PI3k/Akt/mTOR signaling pathway is found in many human cancers and alterations in this pathway are associated with the development and progression of cancer. Drugs that target and inhibit mTOR activity are therefore expected to provide therapeutic value in a number of cancer types. Several classes of mTOR-targeted therapeutics are currently being evaluated in cancer clinical trials, including the rapamycins, dual PI3K-mTOR inhibitors, and ATP-competitive mTORC1/2 inhibitors. This review summarizes important findings from recently completed trials of mTOR inhibitors and also discusses preliminary data from ongoing trials.

Original languageEnglish (US)
Pages (from-to)24-35
Number of pages12
JournalReviews on Recent Clinical Trials
Issue number1
StatePublished - 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology


  • ATP-competitive mTORC1/2 inhibitors
  • Cancer clinical trials
  • Dual PI3K-mTOR inhibitors
  • Rapamycins
  • mTOR
  • mTOR-targeted therapeutics


Dive into the research topics of 'Recent clinical trials of mTOR-targeted cancer therapies'. Together they form a unique fingerprint.

Cite this